Research map: NKG2D CAR-NK adoptive cellular immunotherapy combined with or without PD-1 blockade in the treatment of patients with metastatic colorectal cancer: an exploratory study

Back to the article

Papers in this map

  1. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries · Freddie Bray · 2024 · 26051 citations · Cited by this paper
  2. Engineering immunity with CAR-NK cells: advancing the frontiers of cancer immunotherapy · Vlad Andrei Cianga · 2025 · 6 citations · Cites this paper
  3. HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression · 2026 · Related
  4. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study · Michael James Overman · 2017 · 2892 citations · Cited by this paper
  5. Advances in chimeric antigen receptor-natural killer cell therapy: from mechanisms and preclinical studies to clinical application · Tianyuan Ren · 2026 · 6 citations · Cites this paper
  6. Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma · 2026 · Related
  7. Diagnosis and Treatment of Metastatic Colorectal Cancer · Leah H. Biller · 2021 · 2718 citations · Cited by this paper
  8. Cell Therapies and Bispecific Engagers: Redefining Strategies against Checkpoint Resistance · Heinz Philipp Laubli · 2026 · 4 citations · Cites this paper
  9. Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma · 2026 · Related
  10. Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2 · Richard A. Morgan · 2010 · 2585 citations · Cited by this paper
  11. Strategies for the Development of NK Cell-Based Therapies for Cancer Treatment · Tatiana Budagova · 2025 · 3 citations · Cites this paper
  12. Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma · 2026 · Related
  13. Immunotherapy in colorectal cancer: rationale, challenges and potential · Karuna Ganesh · 2019 · 2093 citations · Cited by this paper
  14. Interplay between natural killer cells and ferroptosis: novel insights in tumor immunity and therapeutic potential · Jing Sun · 2026 · 3 citations · Cites this paper
  15. Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma · 2026 · Related
  16. Natural killer cells in antitumour adoptive cell immunotherapy · Tamara J. Laskowski · 2022 · 784 citations · Cited by this paper
  17. Driving CAR therapies beyond T cells · Cecilie Oelvang Madsen · 2026 · 1 citation · Cites this paper
  18. Integrative single-cell and multi-omics analysis of ZBTB21-mediated serine metabolism in colorectal cancer: from metabolic reprogramming to immune microenvironment modulation · 2026 · Related
  19. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy · Natalie K. Wolf · 2022 · 580 citations · Cited by this paper
  20. Cancer immunotherapy: Current progress and future perspectives · Aqu Alu · 2026 · 1 citation · Cites this paper
  21. Squeezing Treatment-Induced Metabolic Alterations in Melanoma Cells Are Accompanied by Impaired Cluster of Differentiation 8-Positive T Cell and Natural Killer Cell Antitumor Effector Functions · 2026 · Related
  22. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial · David Marín · 2024 · 503 citations · Cited by this paper
  23. Resistance to CAR-based cell therapy: Mechanisms and overcoming strategies · Sha Sha · 2026 · Cites this paper
  24. MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy · Annelisa M. Cornel · 2020 · 479 citations · Cited by this paper
  25. Safety and feasibility of 5T4 antibody-coupled allogeneic NK cell therapy for solid tumors: a first-in-human phase 1 trial · L G Sun · 2026 · Cites this paper
  26. CIS is a potent checkpoint in NK cell–mediated tumor immunity · Rebecca B. Delconte · 2016 · 400 citations · Cited by this paper
  27. Beyond CAR-T and oncology: broadening chimeric antigen receptor technologies across cell types and diseases · Xiaohong Liu · 2026 · Cites this paper
  28. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors · Lei Peng · 2024 · 369 citations · Cited by this paper
  29. Combined carbon ion radiotherapy and immunotherapy: leveraging the immunological advantages of carbon ion · Ruimin Chen · 2026 · Cites this paper
  30. Cancer treatment and survivorship statistics, 2025 · Nikita Sandeep Wagle · 2025 · 253 citations · Cited by this paper
  31. Safety and feasibility of 5T4 antibody-coupled allogeneic NK cell therapy for solid tumors: A first-in-human phase 1 trial · Liangjie Sun · 2026 · Cites this paper
  32. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial · Thierry André · 2025 · 235 citations · Cited by this paper
  33. Engineering with EP2/EP4 knockout and IL-15 transpresentation renders stem cell-derived NK cells self-persistent and resistant to PGE2 inhibition · Marcos Vidal-Manrique · 2026 · Cites this paper
  34. Untitled · Cited by this paper
  35. Enhancing CAR-NK persistence to unlock its full therapeutic potentials · Ovini Amarasinghe · 2026 · Cites this paper
  36. Untitled · Cited by this paper
  37. Advances in Immunological Combination Therapy for Colorectal Cancer · Jiayue Wu · 2026 · Cites this paper
  38. Untitled · Cited by this paper
  39. CEA-targeted CAR-NK cells derived from embryonic stem cells exhibit potent anti-tumor activity against colorectal cancer · Gaohua Li · 2026 · Cites this paper

Source: OpenAlex (CC0)